Unaudited Financial Results of the Company for the Quarter Ended December 31, 2025

Revenue declinedEBITDA margin expansionExceptional itemResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.9%Reaction day

₹88.10

prior close

₹88.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+1.4% vs market

Pharmaceuticals peers, median of 157sector-0.7%+1.6% vs sector

On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.1

15m

+0.1

30m

+1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.9-0.5+1.4-0.7+1.6

Next day

-1.0-2.0+1.0-1.4+0.5

+1.0-2.7+3.7-2.1+3.2

+0.5-1.7+2.2-1.6+2.1

-3.4-1.4-2.0-1.6-1.8

-3.5-2.8-0.7-2.4-1.1

-7.4-2.8-4.6-2.9-4.6

15d

-9.1-8.4-0.7-6.3-2.7

-5.8-9.1+3.3-6.6+0.9

+9.0-4.0+13.0-3.5+12.4

+43.1+2.6+40.5+0.7+42.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Godavari Drugs reported Q3 FY26 revenue of Rs 2,218 lakhs, down about 25% from Rs 2,955 lakhs in the same quarter last year. For the nine-month period, revenue fell around 17% to Rs 7,265 lakhs versus Rs 8,785 lakhs a year ago. Despite the sharp drop in sales, net profit for Q3 was nearly flat at Rs 75.76 lakhs (vs Rs 76.74 lakhs), while nine-month profit declined about 20% to Rs 280 lakhs. The company reported an exceptional item of Rs 25.13 lakhs in Q3 that boosted pre-tax profit. Earnings per share stood at Rs 1.01 for the quarter (Rs 3.72 for nine months). The statutory auditor, Ayyadevara & Co., issued an unqualified (clean) limited review report.

Likely market impact

The steep year-on-year revenue decline is a negative signal for growth, but the company has managed to protect profitability through cost control. Near-term stock sentiment may be weak given falling top-line numbers, though the absence of any auditor qualifications and stable margins limit downside risk.